Indegene Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Strong headline growth, acquisition-driven: Revenue grew 30.8% YoY, but organic growth was 18.3% YoY, as the BioPharm acquisition closed October 1 and added roughly 12.5 points of the top-line expansion.
• Margins inched up despite investment drag: Adjusted EBITDA margin expanded 30 bps QoQ to 18.5%, absorbing 150 bps of planned GTM and Gen AI investments plus elevated upfront costs on large new deals.
• PAT fell on non-operating headwinds: PAT declined 6.5% YoY, driven entirely by lower interest income and higher amortization of acquisition intangibles, a combined ~156 bps hit at the PAT level that masks underlying operating momentum.
• Seven large deals signal demand conversion: The quarter added seven >\$1M ACV deals across three accounts, including a \$10M+ annual omnichannel win and a \$20M TCV end-to-end commercialization partnership, though management noted large-account pipeline conversion is still taking longer than expected.
• What to watch next quarter: Whether the 2.5-quarter lag on the \$10M+ deal keeps revenue recognition on track for Q2 FY27, the pace of BioPharm cost synergy realization, and any signal on margin recovery beginning Q1 FY27 as guided.

Revenue Growth & Customer Momentum

• Organic engine still mid-to-high teens: Excluding BioPharm, organic revenue grew 18.3% YoY and 5.9% QoQ, while USD organic sequential growth was 3.9%, confirming the underlying business is scaling steadily even as acquisitions layer on inorganic expansion.
• Large accounts deepening: \$1M+ customers grew by 12 to 52, active customers by 10 to 86, and three of the top five are now \$25M+ accounts, driven by dedicated teams, industry consolidation ending, and clients returning to decision-making.
• Revenue per employee crosses a milestone: The metric passed \$70,000 annually, which management called the highest in the industry, attributing it to technology and AI impact plus the specialized nature of the work.
• Geographic concentration holds steady: 97% of revenue comes from the U.S. and Europe, with North America at 71.8% and Europe at 25.5%; the BioPharm acquisition, being entirely U.S.-based, increased the North America and Commercial segment shares.
• Pipeline robust but conversion lagging: Management described the large-account pipeline as robust but acknowledged conversion has taken more time than expected, though customers where there were issues are gaining momentum and returning.

Gupta: "Our revenue per employee now has crossed \$70,000 annual mark. This is, by far, the highest in the industry, underscoring the tangible impact of technology and AI and the very specialized nature of work we do."

Deal Wins & Commercial Traction

• Omnichannel orchestration at scale: A top-10 pharma engaged Indegene for omnichannel orchestration across its entire U.S. multiproduct portfolio, combining the Invisage platform with BioPharm's Tandem IP and using AI to drive prescription without an on-the-ground sales team; expected to generate \$10M+ in annual revenues with a 2.5-quarter lag post go-live, meaning revenue accrues from Q2 FY27.
• End-to-end commercialization partner: A midsized biotech signed two work orders totaling \$20M TCV, with Gen AI as a key part of the proposition, and is expected to deliver \$5M in revenue in the first 12 months.
• Medical device and R&D expansion: A multiyear \$7.5M TCV pharmacovigilance deal went live in January 2026 using AI-driven automation, while a midsized pharma engaged Indegene to reimagine R&D operations through Gen AI, deploying the AI-assisted NEXT Medical Writing Platform within a private cloud AWS environment for regulatory use cases.
• Agency-less model gaining ground: Indegene is actively engaging clients on AI-led modular solutions that replace traditional fragmented agency structures, positioning the firm as a consolidated strategic partner rather than a point-solution provider.
• Content and audience platforms scaling: A top-20 pharma adopted the replicator module of the Content Super App for European markets, with ability to scale across additional formats and channels globally, while the Audience Intelligence Platform now combines BioPharm's Tandem IP with Invisage for modular AI-powered omnichannel analytics.

Gupta: "We are positioning ourselves and getting recognized as a strategic cutting-edge partner to deliver superior outcomes and not a point solution or a legacy provider stitching partnerships with point solutions to stay relevant."

BioPharm Acquisition & Integration

• Deal closed, integration on track: The acquisition became effective October 1, 2025, and integration of IT, HR, and finance is on schedule for completion by March 31, 2026, with technology IT integration concluding by year-end and no disruption to active engagements.
• Early cross-sell wins: Joint business development has already delivered two omnichannel wins with large Indegene customers integrating BioPharm capabilities, and client response has been positive with strong employee retention.
• Cost synergies identified: Approximately \$1M per annum in cost synergies is expected progressively in FY27, with actions already taken in Q3 and benefits to be visible from Q1 FY27.
• Acquisition discipline highlighted: Management emphasized the deal was done at a sub-10 EBITDA multiple for a company with IP and technology platforms, and conservative accounting treatment has been applied.
• Segment reorganized around the acquisition: Brand Activation and BioPharm have been integrated into the Enterprise Commercial Segment, collapsing the prior structure into three segments: Enterprise Commercial, Enterprise Medical, and Others, reflecting blurred lines and the opportunity to drive larger enterprise-level deals.

Gen AI Strategy & Adoption

• Gen AI is core, not a shift: Management framed Gen AI as integral to the existing proposition, noting that all revenues were already digital and pricing was per-unit from day one, meaning the firm has always been incentivized to drive automation and efficiency, and Gen AI accelerates that model rather than disrupting it.
• Centralization as the Gen AI catalyst: Large pharma companies operating across 50 countries and 25 to 30 brands cannot decentralize AI adoption by training all brand managers; they must drive centralization, which plays to Indegene's enterprise-level capabilities and creates an opportunity to move upstream into brand-level processes.
• Commercial adoption outpaces Medical: The pace of Gen AI adoption is higher on the Commercial side, where risk management and compliance functions are less conservative, while the Enterprise Medical side is more deliberate, though both areas are seeing pipeline and demand shape up with Gen AI embedded.
• Investment already absorbed: Gen AI investments are factored into past performance, with 1.8% of revenues allocated to CTO and technology forays plus a major portion of the 150 bps growth investment directed toward Gen AI acceleration, so no significant incremental margin impact is expected.
• Productivity benefits shared proactively: Indegene has offered certain benefits to customers from Gen AI-led productivity gains, largely in exchange for volume and scope expansion by adding new deliverables, a dynamic management expects to yield positive results as volumes ramp.

Gupta: "Now with AI, customers are saying that I could do much more. And AI is not going to be done in a decentralized way. You think about a large pharma company with operations in 50 countries, 25-30 brands. They can't be having all their brand managers trained and requesting them to do AI. They will have to drive more centralization."

Renewals, Pricing & Contract Dynamics

• Annuity base stable with scope expansion: Most annuity contracts were renewed in the quarter, with net value in line with expectations from the order book at the start of the year, and new customers on 3-to-6-month engagements converted to annual annuity business, driving volume and value increases on renewals.
• Pricing trends benign: Cost-of-living adjustments have been accepted by more customers with very few negotiations, producing a net positive impact, though this applies only to the time-and-material portion of business; the larger business operates on catalogue pricing or fixed-price contracts.
• Gen AI-enabled scope trades: Indegene identified pockets where Gen AI solutions allowed offering price benefits in exchange for volume and scope expansion, proactively sharing productivity gains to expand deliverables, a strategy expected to yield positive results as volumes ramp through the period.
• No hard volume guidance: When pressed for a hard number on future volumes from expanded scope, management could not quantify it, pointing instead to the qualitative trend of new customers converting to annuity and renewals holding stable.

Margins, Profitability & Cash Flow

• Margin walk: Adjusted EBITDA margin expanded 30 bps QoQ to 18.5%, absorbing 150 bps of planned GTM investments, elevated upfront and go-live costs on large recent deal wins, and 110 bps of one-time costs, with no additional wage hike in Q3 after the Q2 increase.
• PAT decline is non-operating: PAT fell 6.5% YoY due to lower interest income from a \$65M reduction in U.S. surplus after the BioPharm acquisition plus lower yields in India and the U.S., and higher D&A from amortization of acquisition intangibles, which rose from ₹23.4 cr to ₹39.6 cr; the combined impact was ~205 bps at PBT and ~156 bps at PAT.
• Amortization path mapped: Elevated amortization is expected to persist for three more quarters, then decline by ₹5 cr per quarter starting Q3 FY27, with a further ~₹2.5 cr per quarter decline beginning Q3 FY28, meaning FY28 starts seeing bumps from lower amortization and FY29 gets more or less normalized.
• Cash flow conversion strong: Cash flow to adjusted EBITDA ratio reached 90% in Q3, and management expects this enhanced conversion to continue given the increased non-cash charge in the P&L.
• Labour code impact immaterial: New Indian labour code regulations on salary components will have no material impact because Indegene's compensation structures already meet the 50% threshold of base pay as part of total comp, and gratuity and leave encashment provisions have been at an enhanced level exceeding 50% for many years.
• Near-term margin path: Q4 is expected to be fairly stable, with midyear wage hikes that are minimal and U.S. payroll tax and benefits resets for ~700 U.S. employees enhancing costs, partially offset by operational improvements; margin increases are expected to begin from Q1 FY27.

Gupta: "As an investor, if you look at our track record, in FY22, we took a hit on our margins to take more market share and then bought back the margins within a few quarters. And we have very clearly laid down that in the next 6 to 8 quarters, we will get our margins back to the levels we were at."

Guidance & Commitments

Key Metrics